Hydronopol derivatives as agonists on human ORL1 receptors

US7241770B2 · kind B2 · utility

Assignee

• Solvay Pharmaceuticals, GmbH · US

Inventors

• Matthias Mentzel · Hannover, DE
• Dania Birte REICHE · Bingen, DE
• Reinhard Brückner · Hannover, DE
• Samuel David · Dorval, CA
• Bartholomeus J. Van Steen · Utrecht, NL
• Uwe Schon · Burgdorf, DE
• Daniel Jasserand · Paris, FR
• Ulf Preuschoff · Laatzen, DE

Key dates

• Filing date: Dec 9, 2004
• Grant date: Jul 10, 2007
• Expiry date: May 14, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved.The invention relates to compounds of the general formula (1)wherein the symbols have the meanings as given in the description.